In overweight or obese adults without diabetes, semaglutide increased weight loss and GI disorders

Affiliations

¹ Johns Hopkins University, Baltimore, Maryland, USA (S.R.).
² George Mason University and John Hopkins University, Fairfax, Virginia, and Baltimore, Maryland, USA (L.J.C.).

Comment

Selvi Rajagopal et al. Ann Intern Med. 2021 Jul.

. 2021 Jul;174(7):JC80.

doi: 10.7326/ACPJ202107200-080. Epub 2021 Jul 6.

¹ Johns Hopkins University, Baltimore, Maryland, USA (S.R.).
² George Mason University and John Hopkins University, Fairfax, Virginia, and Baltimore, Maryland, USA (L.J.C.).

Abstract

Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989. 33567185.

Once-Weekly Semaglutide in Adults with Overweight or Obesity.
Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Wilding JPH, et al. N Engl J Med. 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10. N Engl J Med. 2021. PMID: 33567185 Clinical Trial.